You are currently browsing the archives for 17 December 2016.
Displaying 1 entry.

In addition to diabetes.

Recently, the data from the company SPIRIT IV trial XIENCE V to the TAXU Express2 paclitaxel-eluting coronary stent system presented at the Transcatheter Cardiovascular Therapeutics annual meeting in September 2009. 690 patients, the SPIRIT IV trial is one of the biggest head – to-head randomized clinical trials between two drug eluting stents and includes more than 1,100 patients with diabetes.. In addition to diabetes, XIENCE PRIME and XIENCE V to deal with the CE mark for expanded indications for patients who have complex disease, including dual vessels, small vessels and detained side branches .

1 XIENCE PRIME is an investigational device in the United States and not is offered for sale.2 Ryden L, Standl E, Bartnik M, Guidelines on diabetes, pre-diabetes and cardiovascular disease: Summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association study of Diabetes .